A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Boronic Acids
  • Multienzyme Complexes
  • Neoplasms
  • Pyrazines

abstract

  • Given the results of this trial, it is safe and reasonable to recommend treatment with PS341 on the schedule used in this trial at 1.56 mg/m2/dose in Phase II trials. Particular care should be taken with patients with preexisting neuropathy. Further testing in Phase II trials is warranted.

publication date

  • January 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 12171876

Additional Document Info

start page

  • 2505

end page

  • 11

volume

  • 8

number

  • 8